Medicare Part D coverage determination and redetermination appeals: what your team needs to know in 2026

If you've watched a Medicare patient leave the pharmacy counter empty-handed because their Part D plan denied a medication they genuinely need, you know how frustrating this process gets. For the patient, for your staff, for everyone involved in that person's care. The coverage determination and redetermination process under Part D has always been complicated, and heading into August 2026 there are nuances your billing and RCM teams should have firmly in hand. Whether you're working a formulary exception, a step therapy denial, or a quantity limit rejection, handling these appeals efficiently matters for patient outcomes and for your team's sanity.

Understanding the difference between coverage determinations and redeterminations

This distinction trips up a lot of people.

A coverage determination is the initial decision a Part D plan makes about whether it will cover a specific drug for your patient. That includes decisions about formulary placement, prior authorization requirements, step therapy, and quantity limits. When the plan says no, or simply doesn't respond, that's a coverage determination outcome.

A redetermination is the first appeal level. It's the plan's internal review of its own decision. If the redetermination also goes against your patient, the next step is an Independent Review Entity (IRE) appeal, then an Administrative Law Judge hearing, and so on up the ladder.

What catches teams off guard most often: the timelines are tight and non-negotiable. Plans must respond to standard coverage determination requests within 72 hours. For expedited requests, where a delay would seriously jeopardize the patient's health, that window drops to 24 hours. Redeterminations run on similar timelines: 7 days for standard, 72 hours for expedited.

Incomplete documentation and missed windows are where most appeals collapse before they get a fair look.

What to include in a strong coverage determination request

A coverage determination request is your first clinical pitch. Thin requests get thin results.

For any coverage determination, your submission should typically include:

• A clear statement of medical necessity. Not just a checkbox, but a narrative explaining why this drug for this patient is medically appropriate.


• Relevant clinical documentation. Diagnosis codes, recent lab results, treatment history, and anything that establishes the patient's condition and prior treatment attempts.


• The prescriber's attestation. Especially important for step therapy exceptions, where you need to show that required prior therapies were contraindicated, tried and failed, or clinically inappropriate.


• Supporting clinical literature. Not always required, but often the deciding factor for off-label or non-formulary requests.

One thing that's easy to overlook: make sure the prescriber's NPI and contact information are unambiguous in your submission. Plans will use any excuse to delay or reject for "incomplete information," and a missing NPI is a common and entirely avoidable culprit.

Step therapy exceptions: still the toughest fight in Part D

Step therapy denials deserve their own section because they generate disproportionate appeal volume and consistent confusion. Under Part D, plans can require patients to try lower-cost drugs before approving a preferred agent. That requirement isn't going away. But legitimate exception pathways exist, and they're worth knowing well.

Your patient qualifies for a step therapy exception if:

• The required step therapy drug is contraindicated for that patient (allergy, drug interaction, comorbidity, etc.)


• The patient already tried and failed the required drug, whether at another practice, in a prior plan year, or before Medicare enrollment


• Completing the required steps would seriously jeopardize the patient's life or health

The "already tried and failed" scenario is where solid EHR documentation pays off. If a patient took metformin three years ago and had to stop due to GI intolerance, that's your exception argument. It only works, though, if you can document it. Pull the records, get the prescriber to sign off on the history, and present it clearly.

A practical note: some plans require specific forms for step therapy exception requests. Always check before submitting a generic letter. Using the wrong template is a delay tactic some plans will happily exploit.

Handling redeterminations when the first answer is no

A redetermination denial isn't the end of the road, but it does mean your team needs to sharpen the argument before escalating. The redetermination is handled internally by the same organization that issued the initial denial, so approval rates here aren't impressive. They're not zero either, particularly when the first submission was missing documentation.

When preparing a redetermination appeal, don't just resubmit the same package. Work through these questions first:

• What specific reason did the plan cite? Your rebuttal should address their stated rationale directly, not argue around it.


• Is there additional clinical documentation that wasn't included the first time?


• Did the prescriber provide a detailed letter of medical necessity? A generic one-liner won't move anything. A specific, individualized letter from the treating provider carries real weight.


• Are there peer-reviewed studies or clinical guidelines that support the medication for this diagnosis? CMS guidelines, ACC/AHA guidelines, NCCN criteria are all fair game.

If your team processes high appeal volume, drafting tools can help. AI-powered appeal letter generators are increasingly used by billing staff to speed up drafting while maintaining clinical specificity, so no one is starting from a blank page on every case. Any generated content still needs review and personalization before it goes out. These tools work as a starting point, not a finished product.

Documentation habits that save time when appeals come up

The appeals that win are usually won before the denial happens. A few habits that make a measurable difference:

• Document prior authorization attempts and outcomes in the patient chart, including dates, drugs tried, and the reason for discontinuation, not just the final result.


• Flag non-formulary drugs at the point of prescribing so your team can pursue authorization before it becomes an urgent situation at the pharmacy counter.


• Keep a running log of your most common denial reasons by plan. Patterns show up quickly. Knowing that Plan X reliably denies Brand Y on first pass lets you build a stronger initial request from the start.


• Maintain working relationships with your plan contacts. Knowing who to call for an expedited review escalation can shave hours off a turnaround when it matters.

Your August 2026 action plan

Part D appeals aren't getting simpler, and the administrative load on practice and billing staff is real. A sound process won't eliminate denials, but it can meaningfully improve first-pass approval rates and cut the time your team spends chasing redeterminations.

Start by auditing your last 90 days of Part D denials. Look for patterns across drugs, plans, and denial reasons. Then work backward to identify whether the issue sits in documentation, submission format, or the prescribing workflow itself. That audit almost always surfaces specific, fixable problems that are costing your team time every week.

The appeals process exists because coverage decisions aren't always right the first time. Knowing how to work it well is part of the job.